| DHR |
Report |
Q2 revenue |
IN-LINE |
pred ~$6.130B vs. cons $6.096B |
MEDIUM |
| DHR |
Report |
Q2 operating EPS |
BEAT |
pred ~$1.860 vs. cons $1.838 |
MEDIUM |
| DHR |
Report |
Q2 Biotechnology revenue |
BEAT |
pred ~$1.990B vs. cons $1.962B |
MEDIUM |
| DHR |
Guide |
FY26 core growth |
BETTER |
guide 3%-6% vs. cons 2.93% |
MEDIUM |
| DHR |
Guide |
FY26 adjusted EPS |
UNCHANGED |
guide $8.35-$8.55 vs. cons $8.458 |
MEDIUM |
| DHR |
Guide |
Q3 formal guide |
UNKNOWN |
UNVERIFIED |
LOW |
| DHR |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
LOW |
| DHR |
Return |
5-day cumulative residual |
-3.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — maintained FY framework implies softer out-period estimates |
LOW |